(Q37082064)

18 August 2017

1 reference

title

Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease (English)

1 reference

18 August 2017

0 references

1 reference

1 reference

2

Peter Riederer

1 reference

18 August 2017

Eleni Koutsilieri

1

1 reference

18 August 2017

1 January 2007

1 reference

Parkinsonism and Related Disorders

18 August 2017

1 reference

18 August 2017

13 Suppl 3

1 reference

18 August 2017

S329-31

1 reference

Excitotoxicity: perspectives based on N-methyl-D-aspartate receptor subtypes

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

Rationale for and use of NMDA receptor antagonists in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

Dopamine/glutamate interactions in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970025-7

7 January 2021

10.1016/S1353-8020(08)70025-7

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18267259